Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other EventsItem 9.01 Other Events.
On March16, 2018, Stemline Therapeutics,Inc. (the “Company”) launched an at-the-market offering (the “Offering”) of up to $50,000,000 worth of shares of the Company’s common stock, par value $0.0001 per share, to a Distribution Agreement by and among the Company, J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc., dated March16, 2018. A copy of the Distribution Agreement is attached hereto as Exhibit1.1 and is incorporated by reference herein.
Alston& Bird LLP, counsel to the Company, delivered an opinion as to the validity of the shares, a copy of which is attached hereto as Exhibit5.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
The following exhibit is furnished as part of this report:
STEMLINE THERAPEUTICS INC ExhibitEX-1.1 2 a18-8294_5ex1d1.htm EX-1.1 Exhibit 1.1 DISTRIBUTION AGREEMENT March 16,…To view the full exhibit click here
About Stemline Therapeutics,Inc. (NASDAQ:STML)
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.